Oral Glucokinase Activator Gets Breakthrough Tx Status for Type 1 Diabetes
TTP399 is an investigational oral, hepatoselective glucokinase activator.
Diabetes
Trial Evaluating Dapagliflozin in Hospitalized COVID-19 Patients Misses Endpoints
The DARE-19 trial evaluated dapagliflozin in addition to standard of care in reducing disease progression, clinical complications and all-cause mortality in 1250 adults hospitalized with COVID-19.
Ozempic Injection 1mg Now Available as a Single Monthly Pen
Anavip contains venom-specific F(ab’)2 fragments of immunoglobulin G that bind and neutralize venom toxins.
Aflibercept Cuts Vision-Threatening Complications of Diabetic Retinopathy
But no improvement in visual acuity seen with aflibercept versus sham for eyes with nonproliferative diabetic retinopathy
SGLT2 Inhibitor Use Linked to Reduced Risk of Atrial Arrhythmias in T2DM Patients
This meta-analysis aimed to determine the association between SGLT2i use and arrhythmias in patients with T2DM or HF.
Zegalogue Approved for Severe Hypoglycemia in Patients With Diabetes
Zegalogue is a glucagon analogue that is formulated in a ready-to-use aqueous solution for subcutaneous administration.
Albuminuria Reduction Greater With SGLT2 Inhibitor, ERA Combo
A move toward combination therapies is inevitable in the new paradigm for diabetic kidney disease management, according to the authors of an editorial.
USPSTF Urges Prediabetes, T2DM Screen for Overweight Adults
Physicians should screen overweight, obese adults aged 35 to 70 years and refer those with prediabetes to preventive interventions
Pancreatic Islet Replacement Therapy Fast Tracked for Type 1 Diabetes
VX-880 is an investigational allogeneic human stem cell-derived islet cell therapy that may restore pancreatic islet cell function.
Semaglutide May Aid Weight Loss in Obese Patients With T2DM
Estimated change in mean body weight to week 68 was −9.6 percent with semaglutide 2.4 mg versus −3.4 percent with placebo
